Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07043738

Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial

Transcranial magnetic stimulation(TMS) is a non-invasive form of brain stimulation that is cleared by the United States Food and Drug Administration (FDA) for depression. Conventional TMS involves daily weekday treatments for 6-8 weeks. These treatments are targeted using each person's scalp measurements. With conventional TMS, approximately 50-55% of people show a 50% or more improvement in depressive symptoms (in other words, they "respond" to treatment).

Studies are trying to make TMS work better and faster. A new form of TMS called accelerated TMS (aTMS) involves mutliple treatments a day. One specific aTMS protocol involves 10 treatments per day for 5 days. These treatments are targeted using each person's brain scan (magentic resonance imaging, MRI). With this specific aTMS protocol, approximately 70-90% of people show a 50% or more imporvement in depressive symptoms. While these results are exciting, scientists are not sure why this specific aTMS protocol works better than conventional TMS. It could be the dose and schedule of treatment, or it could be the MRI-based targeting. Answering this question is important because MRI-based targeting is expensive and difficult to do in many settings.

This study aims to determine if MRI-based targeting is better than scalp-based targeting for aTMS for depression. In this study, everyone who enrolls and meets criteria will be randomly assigned to MRI- versus scalp-based aTMS targeting.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

22 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Major depressive disorder (MDD) remains a leading cause of global disease burden and disability. In addition to increasing the risk of death by suicide, MDD also shows a graded positive association with all-cause mortality. Antidepressants are the most frequently prescribed medication class in psychiatry and, once started, are often continued for many year. However, antidepressants have a small-to-moderate effect size that might be inflated by publication bias. Most people with MDD do not achieve remission with their first antidepressant, and the probability of getting well and staying well diminishes with each sequential trial. By the fourth trial, remission rates approach single digits. Depression that does not improve with one or more antidepressant classes is often considered "difficult-to-treat" or "treatment-resistant" depression (TRD). Taken together, these data highlight the need for better and faster treatments for TRD.

TMS for TRD is safe, well-tolerated, and often covered by insurance. Unlike esketamine and ECT, TMS does not require supervised transportation after treatment. However, TMS is: 1) time intensive, requiring daily weekday treatments for 6-8 weeks; 2) imprecisely targeted based on scalp measurements, which means that each person is stimulated at a slightly different site; and 3) ineffective approximately half the time, with response and remission rates around 50% and 33%, respectively. A new form of accelerated TMS (aTMS) by Cole et. al was designed to address these limitations. In the open-label trial (n=21), the Cole et a. protocol significantly reduced Montgomery-Åsberg Depression Rating Scale (MADRS) in a single day and resulted in a 79.5% reduction one month after treatment. Remission rates were 86% and 57% one week and one month after open-label aTMS, respectively. From this perspective, this specific aTMS protocol works better and faster than conventional TMS and even rivals ECT. The only double-blind randomized controlled trial of this Cole et al. protocol was discontinued after an interim analysis (n=29) revealed a large effect size (Cohen's d>0.8) for active vs. sham (52.5% vs. 11.1% MADRS reduction, respectively). In this trial, remission rates were 57% and 46% one week and month after active aTMS, respectively. There are also emerging data on retreatment and durability. In a recent open-label extension study (n=27), 91% of people who achieved remission with an index course of this specific aTMS protocol (n=22) also achieved remission with aTMS retreatment 6 months later.

In July 2023, investigators launched the "AINT Trial" (NCT05680727). Our goal was to calculate an effect size to power a confirmatory trial. Investigators matched Cole et al. on schedule, dose, intensity, and precision. Investigators also matched Cole et al. inclusion/exclusion criteria (based on published trials and feedback from Stanford colleagues) and its primary outcome measure (i.e., MADRS reduction (% change) one month after aTMS). The goal was to isolate the variable of targeting. Based on our results (in preparation), a sample size of 40 per group will provide ~95% power to detect a between-group difference. Therefore, this study will be a fully powered, double-blind, confirmatory efficacy trial (n=80) for imaging- vs. scalp-targeted aTMS for TRD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 22-80
  • English proficiency sufficient for informed consent, questionnaires/tasks, and treatment
  • Primary diagnosis of major depressive disorder per DSM-V criteria (Quick Structured Clinical Interview for DSM-5)
  • >20 on Beck Depression Inventory (BDI)
  • >20 on the Montgomery-Åsberg Depression Rating Scale (MADRS)
  • Moderate to severe level of treatment resistance (Maudsley Staging Method)
  • Stable antidepressant medication regimen, or remain medication free, for 4 weeks prior to treatment and to remain on this regimen throughout the study until the 1-month post-treatment visit.
  • Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial
  • Agreement to lifestyle considerations
  • Abstain from becoming pregnant from screening to one-month after treatment (the MRI visit)
  • Continue usual intake patterns of caffeine- or xanthine-containing products (e.g. coffee, tea, soft drinks, chocolate) throughout treatment
  • Abstain from alcohol, tobacco, and recreational drugs for at least 24 hours before the start of each MRI and TMS session

Treatment and study plan

Transcranial magnetic stimulation

Procedure

Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation (aiTBS) will be administered under the supervision of a physician with TMS expertise.

Other names: TMS, Accelerated intermittent theta burst stimulation, aiTBS

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Baseline to one month post treatment

    Depression severity rating scale (0-60, higher numbers indicate higher depressive symptom severity). The MADRS is a clinician rated scale consisting of 10 items, with each item scored on a 7 point scale.

    For the primary outcome, investigators will assess MADRS as a continuous variable (i.e., MADRS change from baseline to one month after treatment) using a mixed-effects model for repeated measures (MMRM). The model will include group assignment, baseline MADRS score, assessment time point, and time point by treatment interaction as explanatory variables.

    Hypothesis: There will be a significant group x time interaction on MADRS score from baseline, immediately post-treatment (Day 5), one-week post-treatment, and one-month post-treatment.

Secondary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Baseline to one month post treatment

    Depression severity rating scale (0-60, higher numbers indicate higher depressive symptom severity). The MADRS is a clinician rated scale consisting of 10 items, with each item scored on a 7 point scale. For the secondary outcomes, investigators will assess MADRS as a categorical variable (i.e., MADRS response defined as ≥ 50% improvement one month after treatment) using a generalized estimating equations approach (GEE).

    Hypothesis: One month after treatment, there will be a significantly larger response rate (≥ 50% MADRS improvement) in the imaging- vs. scalp-targeted group using a z-test for proportions. This response rate will be used to calculate an absolute risk reduction and a "number needed to scan" (NNS) with confidence intervals.

  2. Relationship between treatment target location and response in scalp-targeted aTMS for MDD

    Time frame: Before treatment to 1 month post treatment

    The correlation between clinical improvement (i.e., BDI-II) and the distance between the actual (stimulated) scalp-based target and the (predicted but not stimulated) imaging-based target. The BDI-II is a depression severity rating scales (0-63, higher numbers indicate higher severity).

    Mediation analyses that includes the mediator variable (i.e., distance) in the multivariable model for the outcome (i.e., MADRS improvement). Investigators will implement a form (i.e., counterfactual-based) causal mediation analysis that estimates the controlled direct and indirect effects and the bias-corrected bootstrap confidence intervals while controlling for confounders such as age, sex, and other related variables (e.g., baseline antidepressant use, etc.).

    Hypothesis: In the scalp-targeted aTMS group, clinical improvement will negatively correlate with the distance between the actual (stimulated) scalp-based target and the (predicted but not stimulated) imaging-based target.

Other outcomes

  1. Beck Depression Inventory (BDI)

    Time frame: Before treatment, daily throughout treatment, 1 week post treatment, and 1-12 months post treatment

    Depression severity rating scales (0-63, higher numbers indicate higher severity)

  2. Beck Anxiety Inventory (BAI)

    Time frame: Before treatment, daily throughout treatment, 1 week post treatment, and 1-12 months post treatment

    Anxiety severity rating scale (0-63, higher numbers indicate higher severity)

  3. Clinically Useful Depression Outcome Scale - Daily Adaptation (CUDOS-D)

    Time frame: Before treatment, daily throughout treatment, 1 week post treatment, and 1 month post treatment

    Depression severity rating scales (0-64, higher numbers indicate higher severity)

  4. Clinically Useful Anxiety Outcome Scale - Daily Adaptation (CUXOS-D)

    Time frame: Before treatment, daily throughout treatment, 1 week post treatment, and 1 month post treatment

    Anxiety severity rating scale (0-80, higher numbers indicate higher severity)

  5. Patient Global Impression of Change (PGIC)

    Time frame: Before treatment to 1 month post treatment

    A single question assessing a patient's perception of their health or condition (scores range from 1-7, one being the participant believes they are not at all ill, seven being an extremely ill individual) and rate their overall change in condition (scores range from 1-7, one being very much improved and seven being very much worse).

  6. Visual Analog Scale (Mood)

    Time frame: Baseline (before treatment), throughout treatment, and 1 month post treatment

    A single question asking participants to rate their current mood on a scale of 1-100 (higher scores indicate positive mood)

  7. DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult (DSM-5-XC)

    Time frame: Baseline (before treatment) to 1 month post treatment

    Transdiagnostic rating scale (each question rated 0-4) Minimum score: 0 Maximum score: 92 Higher score indicates worse outcome or worse overall psychiatric burden

  8. Adult Attention Deficit/Hyperactivity Disorder Self-Report Scale (AARS)

    Time frame: Baseline (before treatment) to 1 month post treatment

    ADHD rating scale (each question rated 1-5, higher scores indicate symptoms highly consistent with ADHD)

  9. Illness Intrusiveness Rating Scale (IIRS)

    Time frame: Baseline (before treatment) to 1 month post treatment

    13 item scale measuring how illness affects function. Scored 13-91, higher score indicates higher illness intrusiveness severity

  10. McLean Screening Instrument for Borderline Personality Disorder (MS-BPD)

    Time frame: Baseline (before treatment) to 1 month post treatment

    10-item questionnaire used to screen for BPD (scores range from 0 to 10; higher scores are associated with higher levels of/more severe BPD symptoms).

  11. Perceived Stress Scale (PSS)

    Time frame: Baseline (before treatment) to 1 month post treatment

    Stress assessment scored 0-40, higher scores indicate higher stress

  12. Self-Compassion Scale (SCS)

    Time frame: Baseline (before treatment) to 1 month post treatment

    Scale for assessing self compassion (scores range from 1-5, with higher scores indicating greater well-being).

  13. Social Readjustment Rating Scale (SRRS)

    Time frame: Baseline (before treatment) to 1 month post treatment

    A tool used to assess the potential stress associated with different life events (scores range from 0 to 430, with higher scores indicating higher levels of stress).

  14. Spiritual Transcendence Scale (STS)

    Time frame: Baseline (before treatment) to 1 month post treatment

    24 items with responses ranging from 1 to 5; a higher score would indicate a higher level of spiritual transcendence.

  15. Young Mania Rating Scale (YMRS)

    Time frame: Before treatment, throughout treatment, to 1 month post treatment

    11 item scale evaluating mania. Scored 0-60. Higher score indicates worse outcome/higher mania

  16. World Health Organization Quality of Life (WHOQOL-BREF)

    Time frame: Baseline (before treatment) to 1 month post treatment.

    26-item questionnaire assessing an individual's perception of their quality of life (scores range from 0 to 100, where higher scores represent a better quality of life).

  17. World Health Organization Disability Assessment Schedule II (WHODAS 2.0)

    Time frame: Baseline (before treatment) to 1 month post treatment

    36-item functional assessment (each question rated 1-5) Minimum: 36 Maximum: 180 Can also be scored by percentiles Higher score indicates more disability

  18. Death-Suicide Implicit Association Task

    Time frame: Baseline (before treatment) to 1 month post treatment

    Computer task measuring reaction time

  19. Emotion Conflict Resolution (ECR)

    Time frame: Baseline (before treatment) to 1 month post treatment

    Computer task measuring accuracy and reaction time to emotional faces

  20. Multisource Interference Task (MSIT)

    Time frame: Baseline (before treatment) to 1 month post treatment

    Computer task measuring accuracy and reaction time

  21. Penn Emotion Recognition Task (ER-40)

    Time frame: Baseline (before treatment) to 1 month post treatment

    Computer task measuring accuracy and reaction time to emotional faces

  22. Tinnitus Handicap Inventory (THI)

    Time frame: Baseline (before treatment) to 1 month post treatment

    25-item self-report questionnaire used to assess the impact of tinnitus on a person's daily life (scores range from 0 to 100; higher scores indicate a greater tinnitus handicap impact)

  23. Anxiety Sensitivity Index (ASI)

    Time frame: Baseline (before treatment) to 1 month post treatment

    16-item self-report questionnaire used to assess the degree to which individuals fear the physical sensations associated with anxiety (scores range from 0 to 64; higher scores indicate greater anxiety sensitivity).

  24. Adult Temperament Questionnaire (ATQ)

    Time frame: Baseline (before treatment) to 1 month post treatment

    77-item self-administered questionnaire that measures the constructs of effortful control, negative affect, extraversion/surgency, and orienting sensitivity (higher scores indicate presence of listed temperament characteristics).

Study contacts

Contact information is provided by the study sponsor or research team.

Interventional Psychiatry Research Group

CONTACT

[email protected]

6175253536

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • National Institute of Mental Health (NIMH)
  • National Institutes of Health (NIH)

Registry information

Acronym: NNS

Important dates

Study start
2026
Primary completion
2031
Study completion
2032
First posted
Jun 29, 2025
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.